[SCHEDULE 13G/A] Quantum Biopharma Ltd. Class B Subordinate Voting Shares SEC Filing

Rhea-AI Filing Summary

Malone Wealth Ventures LLC, a U.S. registered investment adviser, filed Schedule 13G/A (Amendment No. 5) on 10 July 2025 disclosing a significant position in Quantum Biopharma Ltd. (QNTM). The firm reports beneficial ownership of 735,148 Class B subordinate voting shares, equating to 19.4 % of the outstanding class. Malone retains sole voting power over 103,601 shares and sole dispositive power over the full stake; no shares are subject to shared voting or dispositive power. The difference indicates that most shares are held for advisory clients who keep voting rights while Malone manages disposition.

The filer certifies the shares were acquired in the ordinary course of business and not to influence control. No subsidiaries or group members are involved, and no single client holds more than 5 % of the class. Quantum Biopharma’s headquarters remain at 55 University Ave., Suite 1003, Toronto, Ontario.

This near-20 % holding positions Malone as a major stakeholder, improving institutional visibility for Quantum Biopharma and potentially stabilising the shareholder base. Investors should monitor upcoming ownership updates, as any move above the 20 % threshold or a switch to Schedule 13D could signal a change in strategic intent.

Positive

• Malone Wealth Ventures LLC now controls 19.4 % (735,148 shares) of Quantum Biopharma’s Class B stock, signalling strong institutional confidence.
• Filer states the stake was acquired in the ordinary course of business, reducing the likelihood of immediate activist pressure.

Negative

• Only 103,601 shares carry sole voting power, creating a potential gap between economic ownership and governance influence.
• High concentration—just below the 20 % threshold—could reduce trading liquidity and heighten governance risk if intentions change.

Insights

Securities Analyst

TL;DR Malone Wealth’s 19.4 % stake signals material institutional support but stops short of activist control.

The disclosure delivers a clear datapoint: 735,148 shares give Malone Wealth Ventures a sizeable economic interest, yet voting authority is concentrated in only 103,601 shares. That structure suggests the firm manages positions for multiple clients under discretionary mandates. From a market perspective, the filing validates liquidity in Quantum Biopharma’s float and may attract follow-on institutional interest. While no purchase price or timing details are offered, the ordinary-course language lowers the probability of short-term activism. Overall, the event is modestly positive for sentiment and may reduce perceived ownership overhang risk.

Corporate Governance Expert

TL;DR Large beneficial stake with limited voting power raises alignment and concentration questions.

Governance impact is mixed. Malone’s economic exposure is high, but its voting power—14 % of the owned shares—limits direct influence on board matters. The near-20 % threshold warrants monitoring; surpassing it could trigger additional regulatory obligations or prompt a 13D conversion. Concentrated ownership can stabilise share price yet may constrain free float and amplify governance risks should intentions shift. At present, the certification of passive intent keeps the situation neutral, but vigilance is advised.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Quantum Biopharma Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74764Y205

(CUSIP Number)

07/10/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74764Y205

1

Names of Reporting Persons

Malone Wealth Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 103,601.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 735,148.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

735,148.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

19.4 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: Les Gro

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quantum Biopharma Ltd.
(b)	Address of issuer's principal executive offices: 55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, ONTARIO, CANADA, M5J 2H7.
Item 2.
(a)	Name of person filing: Malone Wealth Ventures LLC
(b)	Address or principal business office or, if none, residence: 9201 W State St. Ste 126 Boise, ID 83714
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 74764Y205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 735148
(b)	Percent of class: 19.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 103601
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 735148
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Clients of Malone Wealth Ventures LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the securities reported herein. No individual client is known to have such interest relating to more than five percent of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Malone Wealth Ventures LLC

Signature:	Kevin M Malone
Name/Title:	President & CEO
Date:	07/10/2025

FAQ

How many Quantum Biopharma (QNTM) shares does Malone Wealth Ventures own?

Malone Wealth Ventures reports beneficial ownership of 735,148 Class B shares.

What percentage of QNTM’s outstanding shares is represented by Malone’s stake?

The filing cites ownership of 19.4 % of the outstanding Class B subordinate voting shares.

Does Malone Wealth Ventures have full voting power over its QNTM shares?

No. It has sole voting power over 103,601 shares and no shared voting power.

Why was a Schedule 13G/A filed instead of a 13D?

Malone certified that shares were acquired in the ordinary course of business with no intent to influence control, qualifying for passive 13G filing.

Where is Quantum Biopharma Ltd. headquartered?

The company’s principal office is at 55 University Ave., Suite 1003, Toronto, Ontario, Canada M5J 2H7.